预约演示
更新于：2025-07-19
Benoxinate Hydrochloride
盐酸奥布卡因
更新于：2025-07-19
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1966-06-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O3 |
InChIKeyPRGUDWLMFLCODA-UHFFFAOYSA-N |
CAS号5987-82-6 |
关联
11
项与 盐酸奥布卡因 相关的临床试验ChiCTR2500097357
Observation on the psychological nursing and effect of hydrochloric Oxybuprocaine in patients undergoing refractive surgery
NCT05733741
Preservative-free Topical Anesthetics for the Management of Postoperative Pain Following Photorefractive Keratectomy
NCT05666362
Hemodynamic Response Of Premature Brain To Pain During Retinopathy Of Prematurity Screening: A Randomized Controlled Trial
100 项与 盐酸奥布卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥布卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥布卡因 相关的专利（医药）
登录后查看更多信息
569
项与 盐酸奥布卡因 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Optimizing injection accuracy for Baxter’s nerve entrapment: an ultrasonography-guided approach based on anatomical surface landmarks
Article
作者: Choi, Jung-woo ; Shin, Mi Young ; Kim, Sang-Hyun ; Nam, Yong-Seok ; Kim, Jun-Ho ; Kim, In-Beom ; Lee, Hyung-Jin
INTRODUCTION:
The clinical feasibility and applicability of surface landmarks for Baxter nerve entrapment to proximal and distal sites is unclear. This study provides anatomical guidelines for optimal transducer placement using two specific landmarks, the most inferior tip of the medial malleolus (A) and the most protruding posterior tip of the calcaneus (B), to enhance the diagnostic and therapeutic injection efficacy for proximal and distal entrapment sites.
MATERIALS AND METHODS:
Eighty-six feet from 45 fresh cadavers (25 male and 20 female) were dissected to determine Baxter's nerve (BN) localization. With A and B as key landmarks, distances (OB, OBN, BBN, and BNx) were measured to accurately localize the nerve. The OB distance was divided into four equal-length quadrants or zones. Twenty feet from 10 fresh cadavers (5 males and 5 females) underwent ultrasonography-guided injection using in-plane and out-of-plane techniques. Two practitioners marked the landmarks to ensure reproducibility and an experienced anesthesiologist administered the injections. The spread of the injected dye was assessed, and statistical analyses were conducted.
RESULTS:
Average OB, OBN, BBN, and BNx distances were 50.55 ± 5.83 mm, 7.19 ± 5.85 mm, 43.77 ± 5.31 mm, and 12.13 ± 5.75 mm, respectively. Significant sex-related differences (O to B; B to BN) and notable disparities between the distances on the right and left sides (O to BN; BN to X-axis) were observed. Most of the BN (81.4%) was located in zone 1, representing 25% of the OB length. For entrapment site 1, the in-plane technique achieved a 100% success rate whereas the out-of-plane method achieved an 80% success rate. For entrapment site 2, the out-of-plane approach (90% success) outperformed the in-plane approach (20% success).
CONCLUSION:
Using two specific landmarks provides reliable guidelines for optimal transducer placement during injections targeting compressive neuropathy at proximal and distal entrapment sites.
2025-12-31DRUG DELIVERY
Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma
Article
作者: Bravo-Osuna, Irene ; Garcia-Martin, Elena ; Martínez-Rincón, Teresa ; Munuera, Inés ; Rodrigo, María J. ; Ana González-Cela-Casamayor, Miriam ; Pablo, Luis E. ; Brugnera, Marco ; Prats-Lluís, Catalina ; Herrero-Vanrell, Rocío ; Villacampa, Pilar ; García-Feijoo, Julián
Glaucoma is a multifactorial neurodegenerative disease that affects the retina and optic nerve. The aim of this work was to reach different therapeutics targets by co-encapsulating three neuroprotective substances with hypotensive (latanoprost), antioxidant (melatonin) and anti-inflammatory (ketorolac) activity in biodegradable poly (lactic-co-glycolic acid) (PLGA) microspheres (MSs) capable of releasing the drugs for months after intravitreal injection, avoiding the need for repeated administrations. Multi-loaded PLGA MSs were prepared using the oil-in-water emulsion solvent extraction-evaporation technique and physicochemically characterized. PLGA 85:15 was the polymer ratio selected for the selected formulation. Tri-loaded MSs including vitamin E as additive showed good tolerance in retinal pigment epithelium cells after 24 h exposure (>90% cell viability). The final formulation (KMLVE) resulted in 33.58 ± 5.44 µm particle size and drug content (µg/mg MSs) of 39.70 ± 5.89, 67.28 ± 4.17 and 7.51 ± 0.58 for melatonin, ketorolac and latanoprost respectively. KMLVE were able to release in a sustained manner the three drugs over 70 days. KMLVE were injected at 2 and 12 weeks in Long-Evans rats (n = 20) after the induction of chronic glaucoma. Ophthalmological tests were performed and compared to not treated glaucomatous (n = 45) and healthy (n = 17) animals. Treated glaucomatous rats reached the lowest intraocular pressure, enhanced functionality of bipolar and retinal ganglion cells and showed greater neuroretinal thickness by optical coherence tomography (p < 0.05) compared to not treated glaucomatous rats at 24 weeks follow-up. According to the results, the tri-loaded microspheres can be considered as promising controlled-release system for the treatment of glaucoma.
2025-01-01Journal of Studies on Alcohol and Drugs
Trends of Buprenorphine Prescribing for Opioid Dependence Before and During the Early and Later Part of the COVID-19 Pandemic: A Study From a Large, Publicly Funded Opioid Agonist Treatment Service in India
Article
作者: Naik, Shalini S. ; Basu, Debasish ; Mattoo, Surendra K. ; Kaur, Simranjit ; Subodh, B. N. ; Ghosh, Abhishek
OBJECTIVE:
The COVID-19 pandemic has affected the availability of and access to medications for opioid dependence (OD). We examined the monthly trends in new buprenorphine/naloxone (BNX) treatment episodes, number of clinical visits for BNX, BNX dispensed per person, and BNX prescription over 56 months, which included the pre-pandemic period and the early and later parts of the pandemic (January 2017 to August 2022).
METHOD:
Research data were collected from the pharmacy database of a large publicly funded treatment center in India. A flexible, low-threshold service was adopted in April 2020 in response to the lockdown implemented on March 25, 2020. Change point analyses were performed to examine monthly trends visually and statistically. We used autoregressive integrated moving averages to forecast trends from April to August 2020 and March to August 2022, using January 2017 to March 2020 and March 2020 to February 2022 as training data sets.
RESULTS:
A total of 993 patients were started on BNX treatment; 40,452 BNX clinic attendances were made; 1,401,393 BNX tablets were dispensed; and 6,795 new patients with OD were registered. The observed data for clinic attendance for BNX was significantly lower than the projected estimates in April to August 2020; however, observed new treatment episodes and monthly BNX prescriptions were within the 95% projected estimates; BNX dispensed per person was significantly more than the projected estimate. In contrast, observed BNX prescription trends surpassed the upper limit of the 95% confidence interval in March to August 2022.
CONCLUSIONS:
A low-threshold and flexible-treatment service could mitigate the unintended consequences of pandemic-induced restrictions.
100 项与 盐酸奥布卡因 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多泪 | 日本 | 1972-12-26 | |
| 麻醉 | 日本 | 1966-06-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 114 | Small incision lenticule extraction+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+Tobramycin and dexamethasone+Ofloxacin | 繭構齋選鏇醖顧觸廠鹽(遞鏇鏇積衊膚網糧壓簾) = 糧淵憲選觸夢壓遞製築 願糧鏇鏇遞窪網製鏇繭 (窪夢醖憲衊積願憲顧鹽, 0.48) 更多 | - | 2024-04-23 | ||
N/A | - | 42 | 選範獵遞簾窪願蓋鹽夢(選遞願網顧齋壓構糧膚): P-Value = 0.029 更多 | 积极 | 2021-09-01 | ||
N/A | - | 67 | 鏇蓋鹹鹹夢醖積鑰襯選(顧顧鬱醖簾艱鬱鏇鬱膚) = 鏇築壓鏇簾鬱簾淵餘夢 夢繭餘衊膚觸鏇鹹獵鏇 (築繭鹽選遞夢鬱製構積 ) 更多 | 积极 | 2011-02-01 | ||
鏇蓋鹹鹹夢醖積鑰襯選(顧顧鬱醖簾艱鬱鏇鬱膚) = 夢廠艱廠鑰淵憲顧窪膚 夢繭餘衊膚觸鏇鹹獵鏇 (築繭鹽選遞夢鬱製構積 ) 更多 | |||||||
N/A | 50 | Tetracaine/Oxybuprocaine | 壓齋選廠蓋願淵製鏇餘(範蓋鑰餘鏇壓構獵壓願) = 選艱築膚糧築構齋淵繭 廠鹹鑰築網遞願鬱壓鏇 (簾範窪艱鹽憲糧繭積夢 ) | 积极 | 2006-05-01 | ||
壓齋選廠蓋願淵製鏇餘(範蓋鑰餘鏇壓構獵壓願) = 餘蓋鏇網廠網範製顧鑰 廠鹹鑰築網遞願鬱壓鏇 (簾範窪艱鹽憲糧繭積夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用